Covaxin stares at an uncertain launch in US amid a class-action lawsuit

Two months before Ocugen, the US partner of Bharat Biotech International Ltd, announced its partnership with the company for bringing the covid-19 vaccine to the US, it was facing the threat of its shares being delisted from Nasdaq.
Ocugen failed to maintain…

Click here to view the original article.